Cellectar Biosciences, INC Form 4 insider transactions

Cellectar Biosciences files an amendment to a Form 4 to correct the exercise price of a stock option granted to consultant Loren Stefan.

Cellectar Biosciences CFO Chad Kolean was granted stock options for 92,000 shares, contingent on stockholder approval which was obtained on July 7, 2026.

Cellectar Biosciences Director Frederick W. Driscoll acquired 25,000 stock options with an exercise price of $2.70, vesting fully on July 7, 2027.

Director Asher Chanan-Khan acquired 25,000 stock options in Cellectar Biosciences, Inc. (CLRB) with an exercise price of $2.70, vesting in full on July 7, 2027.

Cellectar Biosciences, Inc. reports the grant of stock options to President & CEO James V. Caruso, contingent on stockholder approval.

Cellectar Biosciences, Inc. reports that Director Andrew Gu acquired 25,000 stock options with an exercise price of $2.70, vesting in full on July 7, 2027.

Cellectar Biosciences COO Jarrod Longcor acquired 118,000 stock options contingent on stockholder approval of the company's incentive plan.

Cellectar Biosciences Director Douglas J. Swirsky acquired 37,500 stock options with an exercise price of $2.70, vesting in full on July 7, 2027.

Cellectar Biosciences Director John Neis acquired 25,000 stock options with an exercise price of $2.70, vesting in full on July 7, 2027.

Cellectar Biosciences, Inc. consultant Loren Stefan was granted a stock option for 15,000 shares.

Chief Operating Officer Jarrod Longcor acquired 8,680 shares of common stock and 26,040 warrants in Cellectar Biosciences.

Cellectar Biosciences CEO James V. Caruso acquired 8,680 shares of common stock and 26,040 warrants in a recent transaction.

Cellectar Biosciences Director John Neis reported a pre-planned sale of 198 common shares at a weighted average price of $3.6969, effective December 12, 2025.

Cellectar Biosciences CEO James V. Caruso acquired 10,000 shares of common stock at $4.99 per share and 10,000 warrants at $0.01 each, effective July 2, 2025, under a Rule 10b5-1 plan.

Cellectar Biosciences' Chief Operating Officer, Jarrod Longcor, acquired 10,000 shares of common stock and 10,000 warrants on July 2, 2025, under a pre-arranged trading plan, following a recent 1:30 reverse stock split.

Cellectar Biosciences' Chief Financial Officer, Chad J. Kolean, has increased his beneficial ownership in the company through the acquisition of 5,000 shares of common stock and 5,000 warrants.

Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences, purchased 30,000 shares of common stock at $0.28 per share on January 10, 2025.

Director Douglas J. Swirsky of Cellectar Biosciences acquired stock options for 90,000 shares on February 14, 2025.

Director John Neis acquired stock options in Cellectar Biosciences, Inc. on February 14, 2025.

Director Stefan Loren acquired stock options in Cellectar Biosciences, Inc. on February 14, 2025.

Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences, acquired stock options for 500,000 shares on February 14, 2025.

Chad J. Kolean, CFO of Cellectar Biosciences, reports the acquisition of stock options.

Frederick W. Driscoll, a director of Cellectar Biosciences, Inc., was granted stock options to purchase 60,000 shares of common stock on February 14, 2025.

Asher Chanan-Khan, a director of Cellectar Biosciences, acquired stock options for 60,000 shares on February 14, 2025.

James V. Caruso, President and CEO of Cellectar Biosciences, Inc., was granted options to purchase 900,000 shares of common stock on February 14, 2025.

Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences, receives stock options after stockholder approval of the amended 2021 Stock Incentive Plan.

James Caruso, President and CEO of Cellectar Biosciences, acquired 900,000 stock options after shareholder approval of the company's amended 2021 Stock Incentive Plan.

Chad J. Kolean, CFO of Cellectar Biosciences, acquired stock options for 290,000 shares following stockholder approval of the amended 2021 Stock Incentive Plan.

Andrei Shustov, Senior Vice President, Medical at Cellectar Biosciences, received stock options for 260,000 shares after shareholder approval of the amended 2021 Stock Incentive Plan.

Darrell Shane Lea, Chief Commercial Officer of Cellectar Biosciences, received stock options for 260,000 shares after shareholder approval of the amended 2021 Stock Incentive Plan.